Surfactant - A review for pediatric surgeons

Journal of Pediatric Surgery

Volumn 35, Issue 12, 2000, Pages 1687-1700

  McCabe, Amanda J ^a,b   Wilcox, Dunacan T ^a,b   Holm, Bruce A ^a,b   Glick, Philip L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT;

CHEMICAL COMPOSITION; HUMAN; LUNG ALVEOLUS SURFACE TENSION; PEDIATRIC SURGERY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FUNCTION; REVIEW;

EID: 0033663269     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2000.19214     Document Type: Article

References (127)

1. History of surfactant research
2. Properties, function and origin of the alveolar lining layer
3. Dependence of pressure-volume characteristics of lungs on intrinsic surface active material
4. Surface properties in relation to atelectasis and hyaline membrane disease
5. Premature delivery of fetal lambs infused with glucocorticoids
6. Pulmonary surfactant will secure free airflow through a narrow tube
7. Pulmonary surfactant maintains patency of conducting airways in the rat
8. Pulmonary surfactant: An interdisciplinary approach
9. Pulmonary surfactant
10. Content of dipalmitoyl phosphatidylcholine in lung surfactant -ramifications for surface activity
11. Surface active materials from dog lung. I. Method of isolation
12. The 35kd pulmonary surfactant-associated protein is encoded on chromosome 10
13. Surfactant apoprotein A is synthesized in airway cells
14. Localizations of the surfactant-associated proteins SP-A and SP-B mRNA in female rabbit lung by in situ hybridization
15. Macromolecular organization of natural and recombinant lung surfactant protein SP28- 36. Structural homology with the complement factor C1q
16. Alveolar type II cells express a high-affinity receptor for pulmonary surfactant protein A
17. Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophage
18. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type1 by rat alveolar macrophages
19. Purification, characterization and cDNA cloning of human lung surfactant protein D
20. Structure, biologic properties and expression of surfactant protein D (SP-D)
21. Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein
22. Structural similarity between lung surfactant protein D and conglutinin, two distinct, C-type lectins containing collagen-like sequences
23. Interactions of surfactant protein D with bacterial lipopolysaccharides: Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage
24. Isolation and characterization of a new member of the scavenger receptor superfamily, Glycoprotein-340 (gp-340), as a lung surfactant protein D binding molecule
25. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D
26. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis
27. Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B
28. Interfacial properties of surfactant proteins
29. Structure and properties of surfactant protein B
30. Developmental and hormonal regulation of the surfactant system
31. Nucleotide and amino acid sequences of pulmonary surfactant protein SP18 and evidence for cooperation between SP28-36 in surfactant lipid adsorption
32. Regulation of surfactant associated pbospholipid synthesis and secretion
33. Isolated lamellar bodies from rat lung: Correlated ultrastructural and biochemical studies
34. Ultrastructure of tubular myelin and lamellar bodies in fast-frozen adult rat lung
35. Immunocytochemical localization of the major surfactant apoproteins in type II cells, clara cells and alveolar macrophages of rat lung
36. Rat lung type II cell and lamellar body: Elemental composition in situ
37. Extramembranous particles in tubular myelin form rat lung
38. Lung surfactant and pulmonary toxicity
39. Effects of a surfactant-associated protein and calcium ions on the structure and surface activity of lung surfactant lipids
40. Role of bovine pulmonary surfactant-associated proteins in the surface active property of phospholipid mixtures
41. Pathways for the uptake of fluorescently labeled liposomes by alveolar type II cells in culture
42. Metabolism and turnover of lung surfactant
43. Regulatory mechanisms of surfactant secretion
44. Secretion of surfactant protein A and phosphatidylcholine from type II cells of human fetal Lung
45. Surfactant protein composition of lamellar bodies isolated from rat lung
46. The pulmonary consequences of a deep breath
47. Calcium mobilization and exocytosis after one mechanical stretch of lung epithelial cells
48. Regulation of lung surfactant secretion by intracellular pH
49. Adrenergic and cholinergic regulation of lung surfactant secretion in the isolated perfused rat lung and in the alveolar type II cell in culture
50. The role of calcium in the secretion of surfactant by rat alveolar type II cells
51. Involvement of protein kinase C in pulmonary surfactant secretion from alveolar type II Cells
52. Localization and expression of beta-adrenocepter subtype mRNAs in human lung
53. Temporal segregation of surfactant secretion and lamellar body biogenesis in primary cultures of rat alveolar type II cells
54. Designer Surfactants: The next generation in surfactant replacement
55. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs
56. Infasurf v Exosurf for the treatment of RDS: A 21 center randomized double-masked comparison trial
57. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
58. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung extract in the prevention of neonatal respiratory distress syndrome
59. Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome
60. Pulmonary surfactant in health and human lung diseases: State of the Art
61. Development of the fetal lung
62. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants
63. A Comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks gestation
64. Acute respiratory disorders
65. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: Evaluation of surfactant phospholipid turnover, pool size, and relationship to severity of respiratory failure
66. Surfactant protein A in the course of respiratory distress syndrome
67. Surfactant function in neonates with respiratory distress syndrome
68. Artificial surfactant therapy in hyaline membrane disease
69. Economic consequences of surfactant therapy
70. Pulmonary physiological and surfactant changes during injury and recovery from hyperoxia
71. Pathophysiology of congenital diaphragmatic hernia: II The fetal lamb model is surfactant deficient
72. Biochemical immaturity of lungs in congenital diaphragmatic hernia
73. Contributions by individual lungs to the surfactant status in congenital diaphragmatic hernia
74. Evaluation of lung function changes before and after surfactant application during artificial ventilation in newborn rats with congenital diaphragmatic hernia
75. Pathophysiology of congenital diaphragmatic hernia. VIII: Inhaled nitric oxide requires exogenous surfactant therapy in the lamb model of congenital diaphragmatic hernia
76. Congenital diaphragmatic hernia: Studies of lung composition and structure
77. Unexpected low lecithin/sphingomyelin ratios associated with fetal diaphragmatic hernia
78. High risk lecithin/sphingomyelin ratios associated with neonatal diaphragmatic hernia: Case Reports
79. Fetal lung maturation in congenital diaphragmatic hernia
80. Surfactant therapy in high-risk congenital diaphragmatic hernia
81. Pathophysiology of congenital diaphragmatic hernia: III. Exogenous surfactant therapy for the high risk neonate with CDH
82. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: Evidence of persistent surfactant deficiency
83. Surfactant abnormalities in infants with severe viral bronchiolitis
84. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity
85. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity
86. Immunomodulatory functions of surfactant
87. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis
88. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
89. Surfactant abnormalities in patients with respiratory failure after multiple trauma
90. Changes in subphase aggregates in rabbits injured by free fatty acid
91. Type II pneumocyte changes during hyperoxic lung injury and recovery
92. The role of pulmonary surfactant in the pathogenesis and therapy of ARDS
93. Effect of ventilation strategies on the efficacy of exogenous surfactant therapy in a rabbit model of acute lung injury
94. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia
95. Surfactant therapy in acute respiratory distress syndrome (ARDS) of children
96. The adult respiratory distress syndrome: First trials with surfactant replacement
97. Bovine surfactant therapy for patients with acute respiratory distress syndrome
98. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome
99. An international, randomized, placebo-controlled trial evaluating the safety and efficacy of aerosolized surfactant in patients with sepsis-induced ARDS
100. Surfactant replacement therapy in late-stage adult respiratory distress syndrome
101. Surfactant abnormalities in babies dying from Sudden Infant Death Syndrome
102. Surfactant abnormality and the sudden infant death syndrome - A primary or secondary phenomenon
103. Alveoli and abnormal surfactant
104. Surfactant abnormalities in ALTE and SIDS
105. Abnormalities of surfactant in children with recurrent cyanotic episodes
106. Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis
107. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds
108. Congenital pulmonary alveolar proteinosis: Failure of treatment with extracorporeal life support
109. Surfactant protein B deficiency: Antenatal diagnosis and prospective treatment with surfactant replacement
110. Lung transplantation for treatment of infants with surfactant protein-B deficiency
111. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice
112. Inhibition of pulmonary surfactant function by meconium
113. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration
114. Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy
115. Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndrome
116. Surfactant treatment of full term newborns with respiratory failure
117. Treatment of severe meconium aspiration syndrome with porcine surfactant
118. Surfactant replacement therapy for meconium aspiration syndrome
119. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation
120. Surfactant treatment before reperfusion improves the immediate function of lung transplants in rats
121. Pulmonary surfactant activity is impaired in lung transplant recipients
122. Surfactant protein (SP-A) alterations in bronchoalveolar lavage of lung transplant patients
123. Surfactant replacement in reperfusion injury after clinical lung transplantation
124. Cardiopulmonary bypass significantly reduces surfactant activity in children
125. Cardiopulmonary bypass reduces pulmonary surfactant activity in infants
126. Alterations of the endoalveolar surfactant after surgery with extracorporeal circulation
127. Surfactant protein A concentrations in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation